[go: up one dir, main page]

UA85374C2 - bazedoxifene treatment regimen - Google Patents

bazedoxifene treatment regimen

Info

Publication number
UA85374C2
UA85374C2 UA20041210175A UA20041210175A UA85374C2 UA 85374 C2 UA85374 C2 UA 85374C2 UA 20041210175 A UA20041210175 A UA 20041210175A UA 20041210175 A UA20041210175 A UA 20041210175A UA 85374 C2 UA85374 C2 UA 85374C2
Authority
UA
Ukraine
Prior art keywords
bazedoxifene
treatment regimen
bazedoxefine
azepan
indol
Prior art date
Application number
UA20041210175A
Other languages
English (en)
Ukrainian (uk)
Inventor
Барри С. Комм
Джеймс К. Эрмер
Марк К. Коллинз
Жеральдин М. Феррон
Пол Буд
Венди А. Дьюлин
Саймон Н. Дженкинс
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Publication of UA85374C2 publication Critical patent/UA85374C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к медицине, в частности к способу лечения или ингибирования потери костной ткани, лечения или ингибирования остеопороза у млекопитающего введением селективного модулятора эстрогеновых рецепторов базедоксифена (1-[4-(2-азепан-1-илэтокси)бензил]-2-(4-гидроксифенил)-3-метил-1Н-индол-5-ол) в соответствии с режимом введения с продолжительными интервалами. Изобретение касается также применения базедоксифена для изготовления врачебного препарата для лечения или ингибирования указанных болезней.
UA20041210175A 2002-06-13 2003-06-13 bazedoxifene treatment regimen UA85374C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13

Publications (1)

Publication Number Publication Date
UA85374C2 true UA85374C2 (en) 2009-01-26

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210175A UA85374C2 (en) 2002-06-13 2003-06-13 bazedoxifene treatment regimen

Country Status (20)

Country Link
US (1) US20040063692A1 (ru)
EP (1) EP1531807A4 (ru)
JP (1) JP2005531613A (ru)
KR (1) KR20050010886A (ru)
CN (1) CN1658868A (ru)
AU (1) AU2003248707A1 (ru)
BR (1) BR0311774A (ru)
CA (1) CA2489098A1 (ru)
CR (1) CR7585A (ru)
EC (1) ECSP045492A (ru)
IL (1) IL165210A0 (ru)
MX (1) MXPA04011634A (ru)
NI (1) NI200400065A (ru)
NO (1) NO20044954L (ru)
NZ (1) NZ537051A (ru)
RU (1) RU2355397C2 (ru)
SG (1) SG162615A1 (ru)
UA (1) UA85374C2 (ru)
WO (1) WO2003105834A1 (ru)
ZA (1) ZA200409991B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
CA2561004A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
AR048534A1 (es) * 2004-04-08 2006-05-03 Wyeth Corp Formulaciones de acetato de bazedoxifeno
MX2007012167A (es) * 2005-03-31 2007-11-22 Wyeth Corp Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno, y usos del mismo.
CN101252921A (zh) * 2005-06-29 2008-08-27 惠氏公司 轭合雌激素类物质和苯卓昔芬的制剂
MX2008002484A (es) * 2005-08-24 2008-04-07 Wyeth Corp Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos.
EP2086550A2 (en) * 2006-11-29 2009-08-12 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (ru) * 1993-07-22 1997-04-21 Lilly Co Eli
NZ314601A (en) * 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
NO20044954L (no) 2004-12-16
BR0311774A (pt) 2007-05-08
JP2005531613A (ja) 2005-10-20
CR7585A (es) 2008-10-03
EP1531807A1 (en) 2005-05-25
WO2003105834A1 (en) 2003-12-24
KR20050010886A (ko) 2005-01-28
US20040063692A1 (en) 2004-04-01
NZ537051A (en) 2007-11-30
RU2355397C2 (ru) 2009-05-20
IL165210A0 (en) 2005-12-18
MXPA04011634A (es) 2005-07-05
CN1658868A (zh) 2005-08-24
AU2003248707A1 (en) 2003-12-31
ECSP045492A (es) 2005-03-10
RU2004136316A (ru) 2005-05-10
EP1531807A4 (en) 2007-10-31
NI200400065A (es) 2005-08-09
CA2489098A1 (en) 2003-12-24
SG162615A1 (en) 2010-07-29
ZA200409991B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
UA85374C2 (en) bazedoxifene treatment regimen
MXPA05012249A (es) Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos.
AU2003217414A8 (en) Dosing regimen for gemcitabine hcv therapy
NO20070723L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse
IL177539A0 (en) Address solving apparatus , address solving method, and communication system using the same
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
NO20070742L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse.
SG116667A1 (en) Internal riser inspection system, apparatus and methods of using same.
EP1499303A4 (en) MULTIPHASE MULTI-COMPONENT CAPSULE SYSTEM
MXPA03006007A (es) Bolsa flexible que tiene sistema para mezclar dos componentes.
TW200505479A (en) Uses of IL-23 agonists and antagonists; related reagents
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
SG149867A1 (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
ZA200210293B (en) Allosteric Adenosine Receptor Modulators.
IL172759A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
GB2426612C (en) Method and apparatus for generating configuration.
MXPA03008397A (es) Derivados de benzimidazol que modulan a receptores de quiomicina.
IL172760A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
IL177957A0 (en) Bazedoxifene ascorbate as selective estrogen receptor modulator
DK1265904T3 (da) Positivt allosteriske AMPA-receptormodulatorer, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemidler
AU2003301206A8 (en) Sensitizer dyes for photoacid generating systems
PT1495030E (pt) Moduladores não esteróides de receptores de progesterona
AU2003278419A8 (en) Firewall system for mobile telecommunication device.
MX2007007496A (es) Derivados de indol con actividad antitumoral.
WO2006104761A3 (en) Unique sequence hybridization probes (usp)